On May 11, 2022, Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) announced that it filed for an initial public offering (IPO) on May 11, 2022.  The company also announced that it has agreed to be acquired by a private company for approximately $23 million.  According to the company's press release, filed in the U.S. District Court for the District of Texas on March 31, 2022, ibezapolstat, our leading antibiotic candidate for the treatment of patients with C. difficile infections, failed the Phase 3 primary endpoint and their clinical trial failed.  The company also announced that it had submitted an application to the National Institute of Allergy and Infectious Disease for an additional $23 million of non-diluted funding to support the ongoing development of ibezapolstat.  According to the SEC's complaint, ibezapolstat failed the Phase 3 primary endpoint and failed as well.  The SEC's complaint, filed in the U.S. district court for the District of Texas, charges Acurx with violating the antifungal provisions of Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Sections 206(1), 206(2), and 206(4) of the Investment Advisers Act of 1940.  Without admitting or denying the SEC's allegations, Acurx has consented to the entry of a final judgment that permanently enjoins it from violating the antifungal provisions of Sections 206(1) and 206(2) of the Investment Advisers Act of 1940 and Rule 206(4)-8 thereunder.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Joanne Lee and Chad Yahn of the SEC's Market Abuse Unit.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of Texas, the Federal Bureau of Investigation, and the U.S. Secret Service.